Canada revises GMP policy for foreign establishments
This article was originally published in SRA
Health Canada has revised its policy on the type of evidence that it wants drug companies to submit to demonstrate compliance with good manufacturing practice regulations at foreign establishments1,2.
You may also be interested in...
A new pre-assessment service for COVID-19 clinical trials that was established by the UK medicines regulator to cut down on review times is being extended to a limited number of other kinds of trials.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.